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Background and purpose   Patella resurfacing during primary 
total knee arthroplasty (TKA) is disputed and new prosthesis 
designs have been introduced without documentation of their 
survival. We assessed the impact on prosthesis survival of patella 
resurfacing and of prosthesis brand, based on data from the Nor-
wegian Arthroplasty Register.
Patients and methods   5 prosthesis brands in common use with 
and without patella resurfacing from 1994 through 2009 were 
included n = 11,887. The median follow-up times were 9 years 
for patella-resurfaced implants and 7 years for implants without 
patella resurfacing. For comparison of prosthesis brands, also 
brands in common use with only one of the two treatment options 
were included in the study population (n = 25,590). Cox regres-
sion analyses were performed with different reasons for revision 
as endpoints with adjustment for potential confounders.
Results   We observed a reduced overall risk of revision for 
patella resurfaced (PR) TKAs, but the statistical significance was 
borderline (RR = 0.84, p = 0.05). At 15 years, 92% of PR and 91% 
of patella non resurfaced (NR) prostheses were still unrevised. 
However, PR implants had a lower risk of revision due to pain 
alone (RR = 0.1, p < 0.001), but a higher risk of revision due to 
loosening of the tibial component (RR = 1.4, p = 0.03) and due to a 
defective polyethylene insert (RR = 3.2, p < 0.001). 
At 10 years, the survival for the reference NR brand AGC Uni-
versal was 93%. The NR brands Genesis I, Duracon, and Tricon 
(RR = 1.4–1.7) performed statistically significantly worse than 
NR AGC Universal, while the NR prostheses e.motion, Profix, and 
AGC Anatomic (RR = 0.1–0.7), and the PR prostheses NexGen 
and AGC Universal (RR = 0.4–0.5) performed statistically signifi-
cantly better. LCS, NexGen, LCS Complete (all NR), and Tricon, 
Genesis I, LCS, and Kinemax (all PR) showed no differences in 
this respect from the reference brand. A lower risk of revision 
(crude) was found for TKAs performed after 2000 as compared 
to those performed earlier (RR = 0.8, p = 0.001).
Interpretation   Although revision risk was similar for PR and 
NR TKAs, we found important differences in reasons for revision. 
Our results also indicate that survivorship of TKAs has improved.
 
 
Use of a patellar component (patella resurfacing) during 
primary total knee arthroplasty (TKA) is still disputed. The 
search for improvements has resulted in the introduction of 
several new designs that are widely used nowadays, although 
there is no documentation about their survival. 
The question of whether or not primary patella resurfac-
ing should be recommended has led to several observational 
studies, randomized clinical trials (RCT), and meta-analyses 
(Forster 2004, Parvizi et al. 2005, Nizard et al. 2005, Pakos et 
al. 2005) and review articles (Meneghini 2008). In a critical 
appraisal of the available evidence, Calvisi et al. (2009) were 
not able to find any clear superiority between either of the two 
treatments due to methodological limitations in the published 
studies. Studies based on data from arthroplasty registers 
have found a higher risk of revision when the patella was left 
untreated (Furnes et al. 2002, the Swedish Knee Arthroplasty 
Register Annual Report 2009, Clements et al. 2010). Furnes 
et al. (2002) found that the increased revision risk was mainly 
related to revisions due to pain. Some recent studies have, 
however, indicated that there is no difference in patients’ per-
ception of postoperative pain in the two groups of treatment 
(Johnston et al. 2009, Lygre et al. 2010) and that the observed 
differences in risk of revision due to pain may be caused by 
the exclusive option of a secondary patella resurfacing of the 
originally patella unresurfaced knee. This is supported by a 
recent study from the Australian Orthopaedic Association 
National Joint Replacement Registry (AOANJRR) that sug-
gested that surgeons may be more inclined to revise a patella Acta Orthopaedica 2011; 82 (2): 282–292  283
2006). The unique identification number assigned to each 
resident of Norway is used to link information on revisions. A 
revision is defined as surgical removal or exchange of a part of 
or the whole implant, or as insertion of a patellar component.
Study sample
By December 10, 2009, 32,417 primary TKAs had been 
reported to the NAR. Only TKAs with all components fixed 
with cement were included in the present study. This was 
because the use of cement was most common (n = 27,361, 
84%) and it was to make the results more comparable to 
results from other studies. We excluded hinged prostheses (n = 
22) and prostheses with posterior cruciate ligament sacrific-
ing design (except for the LCS mobile bearing) or constrained 
condylar design (n = 780). Furthermore, patella resurfaced 
(PR) implants of a specific brand were excluded if used in 
less than 200 operations (n = 354). This also applied to brand-
specific patella non resurfaced (NR) implants (n = 386). In 
addition, we did not include prosthesis brands introduced later 
than 2005 (n = 229), leaving 25,590 prostheses in the study 
population for comparison of the survival of prosthesis brands 
(Figure 1). Where possible, prosthesis brands were catego-
rized as PR and NR (Table 1).
For comparison of PR and NR TKAs, the material was fur-
ther restricted to those brands with both PR and NR TKAs 
that were represented by larger numbers than 200 (n = 11,887) 
(Tricon, Genesis I, AGC, LCS, and NexGen). 
Statistics
We used survival analysis with revision of the implant as end-
point. Information on deaths and emigrations was retrieved 
from Statistics Norway, Oslo, until December 10, 2009. The 
survival times of implants in patients who had died or emi-
grated without revision of the prosthesis were censored at 
the date of death or emigration. Otherwise, the survival times 
were censored at the end of the study on December 10, 2009. 
Primary TKA
reported to NAR
1994–2009
n = 32,417
Study population
for evaluation of
prosthesis brands
n = 25,590
Study population for 
evaluation of e￿ect of
patella resurfacing
n = 11,887
n = 27,361
n = 27,339
n = 26,559
n = 25,819
Not all prosthesis components cemented
n = 5,056
Tumor and hinged prostheses
n = 22
Prostheses not in common use a 
n = 740
PCS and constrained condylar prostheses 
n = 780
Brands introduced after year 2005 
n = 229
Brands not represented with both patella
resurfaced and patella non resurfaced b 
n = 13,703
PROSTHESES EXCLUDED
non resurfaced implant knee with a secondary 
patella resurfacing if the patient presents later with 
knee pain, given that the option is still available 
(Clements et al. 2010)
Few studies have compared survival of different 
prosthesis brands and implant designs, but a previ-
ous study (Furnes et al. 2002) from the Norwegian 
Arthroplasty Register (NAR) did not find any sta-
tistically significant short-term differences in revi-
sion rates between the most commonly used brands 
in Norway. Other national arthroplasty registers 
with longer follow-up have reported statistically 
significant differences between some commonly 
used brands in their annual reports (Australian 
Orthopaedic Association National Joint Replace-
ment Registry Annual Report 2009, The Swedish 
Knee Arthroplasty Register Annual Report 2009). 
Based on data in the NAR, we compared over-
all survival of cemented knee prostheses with and 
without resurfacing of the patella, and assessed the 
survival of some widely used TKA brands.
Materials and methods
The Norwegian Arthroplasty Register (NAR)
The NAR was started as a register for total hip 
arthroplasty in 1987 (Havelin 1999, Havelin et al. 
2000) and had been extended to include all artificial 
joint replacements by January 1994 (Havelin et al. 
2000). Information on primary knee arthroplasties 
and revisions is reported on a standardized form 
by the orthopedic surgeon and individual reports 
on TKAs performed have since been received from 
82 orthopedics departments. Practically all TKAs 
(99%) are reported to the NAR (Espehaug et al. 
Figure 1. Description of the selection procedure.
a Patella resurfaced implants of a specific brand were excluded if used in less than 
200 operations (n=354). This also applied to brand specific patella non resurfaced 
implants (n=386). 
b For comparison of patella resurfaced and patella non resurfaced TKAs the material 
was further restricted to those brands with both patella resurfaced and patella non 
resurfaced TKAs represented with larger numbers than 200 (Tricon, Genesis I, AGC, 
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The reversed Kaplan-Meier method was used to calculate 
the median follow-up (Schemper and Smith 1996). To evalu-
ate the effects of patella resurfacing and of prosthesis brands, 
relative risk (RR) estimates from Cox regression models were 
obtained. Adjustments were performed for possible confound-
ing by age group (< 60 years, 60–70 years, > 70 years), sex, 
previous operation of the knee (operated or not), diagno-
sis (primary osteoarthritis of the knee, other) and prosthesis 
brand. The covariate age group was represented with indi-
cator variables since the assumption of a log-linear relation-
ship between age and the revision rate was not justified. The 
impact of patella resurfacing was further assessed with differ-
ent causes of revision as endpoint. More than one reason for 
revision could be reported by the surgeon. Pain was, however, 
only considered as a reason for revision when not reported 
in combination with other causes. In some of these analyses, 
adjustment for prosthesis brand was done by stratification 
when one or more of the brands was without failures (peri-
prosthetic fracture, dislocation of the patella, dislocation (not 
the patella), and defective polyethylene insert). Analogous 
survival curves for these specific endpoints are presented 
without adjustments for brands. 
Patella non resurfaced TKAs were used as the reference 
when assessing the impact of patella resurfacing, while the 
NR AGC Universal was used as reference when comparing 
prosthesis brands. The latter was chosen because NR AGC 
Universal had been used throughout the study period in large 
numbers. The AGC prosthesis has also been used as reference 
in reports from the Swedish Knee Arthroplasty Register (the 
Swedish Knee Arthroplasty Register Annual Report 2009) 
and its results have been reported with favorable survival rates 
with long-term follow-up (97.8% overall survival at 20 years) 
(Ritter 2009). Tests and inspections of plotted Schoenfeld 
residuals (Grambsch et al. 1995) were performed to investi-
gate whether the proportional hazards assumption of the Cox 
models was valid. The assumption was found to be valid for 
comparison of PR and patella NR prostheses when using any 
revision as endpoint (p = 1.0) and when using specific reasons 
as endpoint (p = 0.07–0.9). Regarding comparison of prosthe-
sis brands, the assumption was valid for all brands except for 
PR Tricon, PR Kinemax, and NR Tricon. Survival curves for 
the adjusted percentage of unrevised implants were estimated 
with treatment option as stratification factor. Survival percent-
ages at 5, 10, and 15 years are presented in the tables. Curves 
and percentages are given for survival times when more than 
50 implants remained at risk of revision. 
Since use of patella resurfacing (Figure 2) and prosthesis 
brands (Table 2) changed throughout the study period, sur-
vival was also compared within 2 separate time periods, 
namely for operations performed from 1994 through 2000 
Table 1. Characteristics of primary total knee arthroplasties reported to the Norwegian Arthroplasty Register from 1994 to 2009
  Numbers of hospitals  Men  < 60 years  Median  OAa PO  b MB  c
Prosthesis  n   n  n > 50  n > 100  %  %  age  %  %  %
Patella resurfacing d    11,887  70  46 37  28  13 72  81  26 34
  Patella resurfaced   2,547  51  12  6  28  16  72  71  27  21 
  Patella non resurfaced   9,340  69  41  32  28  13  73  83  25  38
Prosthesis  brand  25,590  79  61 53  31  15 72  84  27 34
  NR AGC Universal  2,123  31  11  7  31  12  73  86  22  0
  NR Tricon e  633 23  5 1  22 7  73 75  24 0
  NR Genesis I  2,304  28  13  7  26  12  73  75  26  0
  NR LCS f, g  3,526  36  15 10  28  13 72  88  26  100
  NR Duracon h  1,283  18  10  5  33 14  71  87 30 0
  NR  NexGen  754  18 4  2  35 17  71  87 26 0
  NR  Profix  6,304  40  25 20  31  16 71  85  25  0.2
  NR LCS Complete  4,090  36  15  13  33  16  70  90  30  100
  NR  e.motion  434  4 2  1  33 18  70  94 40  100
  NR AGC Anatomic  1,298  18  4  4  37  15  70  88  26  0
  PR AGC Universal  425  21  3  1  24  13  73  66  25  0
  PR Tricon e  392  21 3  0  26 21  71  54 29 0
  PR Genesis I  704  23  5  1  25  14  71  72  28  0
  PR LCS i  532  12 2  1  27 13  73  92 23  100
  PR  Kinemax  294 12  2 0  19 9  74 87  22 0
  PR  NexGen  494  11 1  1  36 21  69  64 28 0
            
a Primary  osteoarthritis  of  the  knee  (%).           
b  Previously  operated  in  the  knee  (%).           
c Mobile-bearing  prostheses  (%).           
d Study population restricted to brands represented by both patella resurfaced and patella non resurfaced prostheses.        
e Tricon C or Tricon M femoral component used on the femoral side and Tricon II used on the tibial side.         
f  375 of the primary patella non resurfaced LCS prostheses were used in combination with an LCS Universal tibial component.     
g 3032 with mobile-bearing rotating platform system and 494 with mobile-bearing meniscal system.           
h One Duracon prosthesis had an all-polyethylene tibial component.                 
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(with follow-up until December 10, 2009) and from 2001 to 
December 10, 2009. Comparisons within each time period 
were only performed when the number of available prostheses 
exceeded 200.
We considered p-values of less than 0.05 to be statistically 
significant. The statistical software programs R version 2.10.1 
(The R Foundation for Statistical Computing) and SPSS ver-
sion 17.0 were used.
Results
Of the 11,887 prostheses included when evaluating resurfac-
ing of the patella, 786 (6.6%) were revised by the end of the 
study period while this applied to 1,204 (4.7%) of the 25,590 
prostheses included when evaluating brands. The distributions 
of age, sex, and patients previously operated in the knee were 
similar for patients with a PR TKA and those who had a patella 
NR TKA. Patella NR TKAs were performed in more hospitals 
and were more likely to have had primary osteoarthritis of 
the knee as diagnosis (Table 1). Among brands, differences 
were observed for most of the baseline characteristics of the 
patients (Table 1). Median follow-up and number at risk 0, 5, 
10, and 15 years after the operation are given in Table 2. 
Patella resurfacing (Table 3 and Figure 3)
After 15 years, the overall survival was 92% (CI: 91–94) for 
PR TKAs and 91% (CI: 90–92) for patella NR TKAs. We 
found a lower risk of revision for PR TKAs than for NR TKAs 
(RR = 0.84, CI: 0.71–1.00; p = 0.05). We did not find any 
statistically significant differences in survival between PR and 
NR TKAs within each time period. 
Reasons for revision (Table 4 and Figure 4)
For most of the reasons for revision registered, we did not find 
any statistically significant differences in survival between PR 
and NR TKAs. However, PR TKAs had a statistically signifi-
cantly lower risk of revision due to pain alone (RR = 0.1, CI: 
0.1–0.2; p < 0.001) (Table 4 and Figure 4h), but there was a 
Figure 2. Time trends in the use of cemented patella resurfaced and 
patella non resurfaced TKAs in Norway, 1994–2008. 2009 was not 
included since follow-up was only until December 10, 2009.
Table 2. Follow-up and numbers at risk by years after operation               
 
 Prosthesis  1994–2009  1994–2000  2001–2009 
    Median  Number at risk by  Median   Number at risk by  Median   Number at risk by
    follow-up  years after operation  follow-up   years after operation  follow-up   years after op. 
    (years)   0  5  10  15  (years)   0  5  10  15  (years)   0  5
Patella resurfacing a                      
  Patella resurfaced   9.1  2,547  1,930  986  76  11  1,831  1,519  986  76  6.0  716  411
  Patella non resurfaced   7.2  9,340  6,522  1957  116  10  4,255  3,506  1,957  116  5.8  5,085  3,016
Prosthesis  brand                      
  NR AGC Universal  6.9  2,123  1,445  376  14  9.8  841  708  376  14  5.7  1,282  737
  NR  Tricon  12  633 494 341 66  12  633  494 341 66    –  –
  NR Genesis I  9.6  2,304  1,854  913  35  10  1,946  1,581  913  35  7.9  358  273
  NR  LCS  6.6  3,526  2,573 323  1  9.7 827  716 323  1  6.0  2,699  1,857
  NR  Duracon  1.7  1,283 248 118  4  11  204  173 118  4  1.5  1,079  75
  NR  NexGen  3.2  754  156 4  –  10  8  7 4  – 3.2 746  149
  NR  Profix  4.4  6,304  2,576 51 –  9.2  320  271 51 –  4.2  5,984  2,305
  NR  LCS  Complete  1.9  4,090  59 –  –  –  –  – –  – 1.9  4,090  59
  NR  e.motion  4.1  434  76 –  –  –  –  – –  – 4.1 434  76
  NR AGC Anatomic  2.7  1,298  152  15  –  10  31  25  15  –  2.7  1,267  127
  PR  AGC  Universal  9.0  425 353 160  4  10  309  257 160  4  7.2  116  96
  PR  Tricon  13  392 313 226 67  13  392  313 226 67  –  –  –
  PR  Genesis  I  11  704 581 396  5  11  672  557 396  5  7.2  32  24
  PR  LCS  8.9  532 446 150  –  9.9 346  293 150  –  7.5  186 153
  PR  Kinemax  10  294 240 138 30  11  265  214 138 30  7.2  29  26
  PR  NexGen  4.9 494  237 54 –  10  112 99 54 –  4.0  382  138
                  
a Study population restricted to brands represented with both patella resurfaced and patella non resurfaced prostheses. 286  Acta Orthopaedica 2011; 82 (2): 282–292
Table 3a. Cox relative revision risk (RR) and survival percentages, estimated with all causes of revision as endpoint 
    
Prosthesis  1994–2009     
    n  Revised  RR  95% CI  p  5 yr  10 yr  15 yr  95% CI a
Patella resurfacing b,c                
  Patella non resurfaced  9,340  614  1      94.8  93.0  91.4  90.4–92.4
  Patella resurfaced   2,547  172  0.84  0.71–1.00  0.052  95.9  94.3  92.1  90.7–93.6 
Prosthesis brands d                
  NR AGC Universal  2,123  120  1      94.9  93.2   –  91.9–94.5
  NR  Tricon  633  72  1.67  1.24–2.24  0.001  93.4 88.6 85.0  81.7–88.3
  NR Genesis I  2,304  222  1.43  1.14–1.79  0.002  92.4  90.4   –  89.1–91.6 
  NR LCS  3,526  177  0.84  0.67–1.06  0.14  95.8  94.1   –  93.2–95.1 
  NR Duracon  1,283  56  1.45  1.05–1.99  0.02  94.5  90.6   –  87.4–93.8  
  NR NexGen  754  23  0.79  0.51–1.24  0.3  95.7   –   –  93.9–97.5 
  NR Profix  6,304  195  0.66  0.52–0.82  < 0.001  96.7  95.7   –  94.9–96.5 
  NR LCS Complete  4,090  111  0.94  0.72–1.22  0.6  95.4   –   –  94.2–96.6 
  NR e.motion  434  2  0.09  0.02–0.37  0.001  99.5   –   –  98.9–100 
  NR AGC Anatomic  1,298  31  0.66  0.45–0.99  0.04  97.1   –   –  95.9–98.2 
  PR AGC Universal  425  14  0.48  0.27–0.83  0.009  97.2  96.6   –  94.9–98.4 
  PR  Tricon  392  44  1.28  0.90–1.82  0.2  95.9 92.7 87.5  83.9–91.2 
  PR Genesis I  704  62  1.17  0.86–1.59  0.3  94.0  92.0   –  90.0–94.0 
  PR LCS  532  41  1.23  0.86–1.75  0.3  93.1  91.7   –  89.1–94.2 
  PR Kinemax  294  23  1.14  0.73–1.78  0.6  95.6  92.6   –  89.3–95.8 
  PR NexGen  494  11  0.40  0.22–0.74  0.004  98.6  96.7   –  94.6–98.8
a Confidence interval for last reported survival percentage.         
b Cox relative risk estimates and survival percentages with adjustment for age group, sex, diagnosis, previous operation 
   of the knee, and prosthesis brand.         
c Study population restricted to brands represented by both patella resurfaced and patella non resurfaced prostheses. 
d Cox relative risk estimates and survival percentages with adjustment for age group, sex, diagnosis, and previous 
   operation of the knee. 
Table 3b. Cox relative revision risk (RR) and survival percentages, estimated with all causes of revision as 
endpoint
     
Prosthesis 1994–2000  a   2001–2009 
    n  Revised  RR p  n  Revised  RR p
Patella resurfacing b,c              
  Patella non resurfaced  4,255  349  1    5,085  265  1 
  Patella resurfaced   1,831  138  0.84  0.09  716  34  0.99  1.0
Prosthesis brands d              
  NR AGC Universal  841  51  1  –  1,282  69  1  –
  NR Tricon  633  72  1.84  0.001  0  –  –  –
  NR Genesis I  1,946  175  1.46  0.02  358  47  2.01  < 0.001
  NR LCS  827  50  0.90  0.6  2,699  127  0.81  0.1
  NR Duracon  204  18  1.41  0.2  1,079  38  1.39  0.1
  NR NexGen  8  1  –  –  746  22  0.72  0.2
  NR Profix  320  12  0.59  0.1  5,984  183  0.62  0.001
  NR LCS Complete  0  –  –  –  4,090  111  0.85  0.3
  NR e.motion  0  –  –  –  434  2  0.09  0.001
  NR AGC Anatomic  31  1  –  –  1,267  30  0.63  0.03
  PR AGC Universal  309  13  0.69  0.2  116  1  –  –
  PR Tricon  392  44  1.46  0.07  0  –  –  –
  PR Genesis I  672  57  1.25  0.2  32  5  –  –
  PR LCS  346  20  0.97  0.9  186  21  –  –
  PR Kinemax  265  22  1.32  0.3  29  1  –  –
  PR NexGen  112  4  –  –  382  7  0.33  0.005
a  Follow-up until December 10, 2009
b–d See Table 3a. Acta Orthopaedica 2011; 82 (2): 282–292  287
statistically significantly higher risk of revision due to loosen-
ing of the tibial component (RR = 1.4, CI: 1.0–2.0; p = 0.03) 
and due to a defective polyethylene insert or wear (RR = 3.2, 
CI: 1.7–6.1; p < 0.001). 
The lower risk of revision due to pain alone for PR prosthe-
ses was also found when restricting the material to TKAs per-
formed from 1994 through 2000 (RR = 0.04, CI: 0.01–0.14; 
p < 0.001) but not to those performed from 2001 through 
December 10, 2009 (RR = 0.7, CI: 0.3–1.8; p = 0.4). Higher 
risk of revision due to loosening of the tibial component for 
PR prostheses was also found to be statistically significant 
for TKAs performed in the first time period (RR = 1.5, CI: 
1.0–2.2; p = 0.04) but not in the last (RR = 1.6, CI: 0.9–2.9; 
p = 0.14). Higher risk of a defective polyethylene insert for 
PR prostheses was also found for TKAs performed in the first 
time period (RR = 3.6, CI: 1.9–6.8; p < 0.001) while a total of 
only two events of failure was observed in the last time period. 
There was also a tendency for higher risk of revision for PR 
TKAs due to deep infection in the first time period (RR = 1.6, 
CI: 1.0–2.5; p = 0.06) but not in the last time period (RR = 0.7, 
CI: 0.3–1.8, p = 0.45).
Prosthesis brands (Table 3, Figure 5, and Figure 6)
At 10 years, the survival for the reference brand—patella NR 
AGC Universal—was 93% (CI: 92–95). We observed some 
variability in survival among prosthesis brands at 10 years of 
follow-up, ranging from 89% for NR Tricon to 97% for PR 
NexGen (RR = 0.2, CI: 0.1–0.45; p ≤ 0.001). For brands rep-
resented by both PR and NR TKAs (Tricon, Genesis I, AGC 
Universal, LCS, and NexGen), the PR TKAs had higher per-
centage survival than the same brand of NR TKAs, except for 
the LCS where NR TKAs showed higher survival. 
Compared to the reference brand, NR Tricon (RR = 1.7, CI: 
1.2–2.2; p = 0.001), NR Genesis I (RR = 1.4, CI: 1.1–1.8; p 
= 0.002) and NR Duracon (RR = 1.4, CI: 1.1–2.0; p = 0.02) 
performed statistically significantly worse while NR Profix 
(RR = 0.7, CI: 0.5–0.8; p < 0.001), NR e.motion (RR = 0.1, 
CI: 0.0–0.4; p = 0.001), NR AGC Anatomic (RR = 0.7, CI: 
0.4–1.0; p = 0.04), PR AGC Universal (RR = 0.5, CI: 0.3–0.8; 
p = 0.009) and PR NexGen (RR = 0.4, CI: 0.2–0.7; p = 0.004) 
performed significantly better. 
A separate analysis performed on patella resurfaced LCS 
Figure 3. Survival rates (%) for cemented patella resurfaced and 
patella non-resurfaced TKAs in Norway, 1994–2009; all revisions. Cox 
regression results with adjustment for age group, sex, diagnosis, previ-
ous operation of the knee, and brand of prosthesis.
Table 4.  Cox relative revision risk (RR), patella non resurfaced TKAs vs. patella 
resurfaced primary TKAs by reason for revision, 1994–2009
       
  Revised Revised 
Reason for  patella  patella non-
revision a  resurfaced  resurfaced    RR b  95% CI  p
        
Loose femur  21  65  0.82  0.49–1.39  0.5
Loose tibia  57  149  1.42  1.03–1.95  0.03
Loose patella  13       
Dislocation, patella  7  22  0.98  0.42–2.32  1.0
Dislocation, other  4  12  2.22  0.71–6.95  0.2
Instability  30  73  0.96 0.61–1.50  0.9
Malalignment  17  43  1.18 0.65–2.12  0.6
Deep infection  41  93  1.32  0.90–1.95  0.2
Periprosthetic fracture  7  20  1.53  0.64–3.70  0.3
Defect polyethylene ins.  30  16  3.23  1.71–6.11  < 0.001
Pain alone  8  202  0.12  0.06–0.23  <0.001
        
a More than one reason for revision may have been reported.   
b Cox relative risk of revision estimates (RR) adjusted for age group, sex, diagnosis, 
previous operation of the knee, and brand (AGC Universal, Tricon, Genesis I, LCS, 
and NexGen) are reported for patella resurfaced vs. patella non resurfaced prosthe-
ses. 
prostheses did not show any advantage of the 
mobile bearing rotating platform system (n = 
323) compared to the mobile bearing menis-
cal system (n = 208) (RR = 1.3, 95% CI: 
0.6–2.4; p = 0.5). A corresponding analysis 
performed on patella NR LCS prostheses did 
not show any advantage of the mobile bear-
ing rotating platform system (n = 3,031, 375 
with LCS Universal tibial insert) compared to 
the mobile bearing meniscal system (n = 477) 
(RR = 0.9, CI: 0.6–1.4; p = 0.7). 
A significantly lower risk of revision was 
found when comparing crude survival of the 
TKAs performed in the last time period to 
those performed in the first (RR = 0.8, CI: 
0.7–0.9; p = 0.001).
Patient-related factors
We found no statistically significant difference 
in survival of TKAs in women as compared to 
men (RR = 1.0, CI: 0.9–1.1; p = 1.0) and for 288  Acta Orthopaedica 2011; 82 (2): 282–292
knees with osteoarthritis as compared to other diagnoses (RR 
= 0.9, CI: 0.8–1.1; p = 0.3). Knee prostheses in older patients 
(> 70 years) were found to perform better than in younger 
patients (< 60 years) (RR = 0.4, CI: 0.3–0.4; p < 0.001), and 
previously operated knees performed more poorly than those 
that were not previously operated (RR = 1.3, CI: 1.1–1.4; p < 
0.001).
Discussion
Summary
We observed a statistically non-significant reduced risk of 
revision of 16% for PR TKAs as compared to patella NR 
TKAs based on data with 0–15 years of follow-up in the NAR. 
There were, however, statistically significant differences in 
reasons for revision. While patella NR TKAs were more often 
revised due to pain, PR TKAs had a higher risk of revision 
due to aseptic loosening of the tibial component and due to a 
Figure 4. Survival rates (%) for cemented patella resurfaced and patella non resurfaced TKAs in Norway, 1994–
2009; specific reasons for revision. Cox regression results with adjustment for age group, sex, diagnosis, previ-
ous operation of the knee, and prosthesis brand [(c), (g), (i) without adjustment for brand].Acta Orthopaedica 2011; 82 (2): 282–292  289
Figure 6. Survival rates (%) for cemented patella non resurfaced pros-
thesis brands in Norway, 1994–2009; all revisions. Cox regression 
results with adjustment for age group, sex, diagnosis, and previous 
operation of the knee.
Figure 5. Survival rates (%) for cemented patella resurfaced prosthe-
sis brands in Norway, 1994–2009; all revisions. Cox regression results 
with adjustment for age group, sex, diagnosis, and previous operation 
of the knee.
defective polyethylene insert or wear when assessed with long 
follow-up.
Regarding brands, NR Tricon, NR Genesis I, and NR Dura-
con performed significantly worse than the reference brand 
NR AGC Universal, with about 1.5 times higher risk of revi-
sion. NR Profix, NR e.motion, NR AGC Anatomic, PR AGC 
Universal, and PR NexGen had a significantly reduced risk 
of revision. NR LCS, NR NexGen, and NR LCS Complete 
performed similarly to the reference brand, as did PR Tricon, 
PR Genesis I, PR LCS, and PR Kinemax. For brands that were 
evaluated both with and without patella resurfacing, patella 
resurfacing appeared to offer the best survival performance, 
except for the LCS design were patella resurfacing had the 
poorest survival.
Explanations/mechanisms 
The (non–significantly) higher risk of revision for patella NR 
TKAs was found to be caused mainly by more revisions due 
to pain only. A recent study from the NAR (Lygre et al. 2010) 
and a high-powered multicenter RCT including 1,715 patients 
(Johnston et al. 2009) could not, however, demonstrate any 
difference in level of pain between the two treatment groups. 
One explanation could be the exclusive option of secondary 
resurfacing of the patella for patella NR TKAs. Hence, lower 
risk of revision due to pain may not necessarily be caused 
by less severe pain but because surgeons may be more likely 
to revise a painful patella NR TKA than a painful PR TKA.
This explanation is also supported in a recent study from the 
AOANJRR (Clements et al. 2010). Our findings also indicate 
that the difference in risk of revision due to pain was greatest 
for TKAs performed in the first time period (1994 to 2001). 
This might be due to the introduction of the newer and more 
patella-friendly implant NexGen and due to the stop in use of 
some older inferior designs that were represented in our mate-
rial by Genesis I and Tricon. The NexGen implant has also 
been found to perform statistically significantly better regard-
ing pain than the implants AGC Universal and Genesis I in a 
recent study from the NAR (Lygre et al. 2010). 
The rate of aseptic loosening of the tibial component for PR 
TKAs has been found to be highest with long follow-up, and 
may also be associated with wear of the extra polyethylene 
element on the patellar side (Ogon et al. 2002). It might thus 
be explained by a higher volume of polyethylene particles in 
the joint (Goodman and Lidgren 1992). Such an association is 
also supported by similar phenomena observed when assess-
ing wear and loosening of cups after hip arthroplasty (Wro-
blewski et al. 2004, Wilkinson et al. 2005). Patella resurfacing 
might also increase the patellofemoral offset due to conserva-
tive bone resection. The resulting increased forces over the 
patellofemoral joint and onto the tibia might thereby increase 
tibial loosening and wear of the tibial polyethylene insert. This 
is also supported by the observation of higher risk of revision 
due to defective polyethylene inserts in PR TKAs apparent 
after about 10 years of follow-up.
Regarding brand-specific results, the good performance 
of the NR e.motion prosthesis and also the inferior results 
of the PR LCS prosthesis as compared to the NR LCS, are 
interesting but could be caused by variables other than the 
implant itself—since the use of NR e.motion and PR LCS 
was restricted to few hospitals. However, the revision rate for 
the PR LCS prosthesis has also been reported to be higher 290  Acta Orthopaedica 2011; 82 (2): 282–292
then anticipated in operations reported to the AOANJRR 
(Australian Orthopaedic Association National Joint Replace-
ment Registry Annual Report 2009). Higher failure rates were 
found to be associated with the use of a metal-backed LCS 
patellar component as compared to an all-polyethylene LCS 
patellar component, which may also explain our findings since 
metal backing was used in all PR LCS TKAs performed in 
Norway during the study period. 
The search for improvement in outcome of TKAs has 
resulted in the introduction of new designs of both the tibial 
and the femoral component. Most brands included in this 
study had a modular fixed-bearing tibial insert, except for the 
AGC implants where the fixed-bearing tibial component was 
a metal-backed mono-block and for the LCS, LCS Complete, 
and e.motion implants where a mobile-bearing system was 
used. For the LCS implant, both a mobile meniscal bearing 
and a mobile rotating platform were used. We could not, how-
ever, identify any clear advantages related to any of these LCS 
designs in this study with more than 10 years of follow-up. 
Further follow-up is needed to determine whether the mobile-
bearing knee prostheses lead to lower wear and less loosening. 
In a recent meta-analysis, no advantage using mobile-bearing 
knee prostheses was found (Oh et al. 2009), which is sup-
ported by our findings.
The shape of the femoral component has been focused on 
in the search for maximal range of motion and minimal ante-
rior knee pain after TKA. The idea is that the patella needs 
an anatomic flange and groove in the femoral component to 
perform satisfactory through bending and stretching; this has 
been reported to show a clear advantage over the unresurfaced 
patella regarding complications as well as pain and function 
(Whiteside and Nakamura 2003). More anatomic femoral 
components with a narrower fork and deeper groove have 
been introduced in newer designs, which may explain the 
better performance of the NR AGC Anatomic, NR Profix, and 
NR e.motion prostheses as compared to the NR Tricon, NR 
Genesis I, and NR Duracon. However, the RR estimates for 
PR Tricon, NR Tricon, and PR Kinemax relative to NR AGC 
Universal might be overestimated due to failure of the pro-
portional hazards assumption of the Cox model (Schemper 
1992). For NR e.motion, the good results may also be caused 
by the congruent interface between the femoral component 
and the tibial insert (Morra and Greenwald 2005). This may 
possibly reduce contact stress and thereby produce less wear. 
The short follow-up of this prosthesis should be noted, how-
ever. 
Thus, even though the observed improvement in survival of 
TKAs over time may to a certain extent be associated with 
better operation techniques and more experienced surgeons, 
part of the difference may be explained by the introduction 
of newer prosthesis brands with better survival that are used 
in high volume (PR NexGen and NR Profix) together with 
termination of the use of brands demonstrated to have poorer 
survival (NR/PR Tricon, NR/PR Genesis I, PR Kinemax, and 
PR LCS). There were also more recently introduced brands 
with good short-term results that might have contributed to the 
increased overall survival of TKAs in the last time period (NR 
AGC Anatomic and NR e.motion). 
 
Comparison with other relevant studies
The available evidence regarding patella resurfacing, based 
on observational studies, RCTs, and meta-analyses, has been 
summarized in a recent systematic review (Calvisi et al. 
2009). While the authors found it difficult to make any strict 
conclusions due to methodological limitations in the available 
studies, they found a lower risk of revision and a lower level 
of postoperative anterior knee pain with the use of resurfaced 
implants. These advantages were, however, found to be at the 
expense of potential complications related to the resurfaced 
patella. 
Few studies have assessed the impact of patella resurfacing 
and of prosthesis brand on implant survival by using data from 
arthroplasty registers. A previous study from the NAR (Furnes 
et al. 2002) found a higher risk of revision, but not signifi-
cantly so, for patella NR implants. The authors did, however, 
find a significantly higher risk of revision due to pain alone for 
patella NR TKAs and due to infection for PR TKAs. While the 
difference in risk of revision due to pain has been confirmed 
by our findings, we could not demonstrate any difference in 
risk of revision due to infection. However, by restricting the 
material to operations performed in a similar time period (from 
1994 to 2000) but with longer follow-up (more than 8 years), 
there was a tendency of a higher risk of revision caused by 
infection. This tendency was not apparent when considering 
the operations performed from 2001 to December 10, 2009. 
Furnes et al. did not observe significant differences in revi-
sion rates among brands, possibly due to short follow-up 
time. A lower risk of revision of PR implants has also been 
reported from other arthroplasty registers (the Swedish Knee 
Arthroplasty Register Annual Report 2009, Clements et al. 
2010). In Sweden, PR Kinemax showed poorer survival than 
PR AGC. NR NexGen performed better than NR AGC, while 
NR Duracon, NR LCS, and NR Profix performed similarly 
(the Swedish Knee Arthroplasty Register Annual Report 
2009). The NexGen implant has also been found to be the 
least revised cemented prosthesis brand at 8 years, as reported 
to AOANJRR (Australian Orthopaedic Association National 
Joint Replacement Registry Annual Report 2009). 
Some of the prosthesis brands included in this study have 
been examined regarding survival in single-center studies. The 
PR AGC prosthesis has shown good long-term results (Ritter 
2009). These results are in accordance with our findings and 
they were partly explained by the non-modular tibial compo-
nent that is thought to offer less backside wear of the polyeth-
ylene insert. Positive long-term results have also been dem-
onstrated for uncemented Profix prostheses (Hardeman et al. 
2006), but to our knowledge our study is the only one to report 
10-year survival results for cemented NR Profix prostheses.Acta Orthopaedica 2011; 82 (2): 282–292  291
Strengths and limitations
For economic and practical reasons, comparisons of rare inci-
dences such as revision of joint replacements by use of high-
powered RCTs are rarely performed. The main alternative to 
RCTs is evidence from large observational studies such as 
arthroplasty registers. Even though it is generally agreed that 
they are less conclusive, qualitatively speaking results from 
well-designed observational studies may compare well with 
those from RCTs (Benson and Hartz 2000). Registry studies 
may also have advantages such as better external validity due 
to representation from a wider range of operation procedures, 
hospitals, implants, patients, and surgeons. 
Comparison of survival of different prosthesis designs in 
observational studies may, however, give results confounded 
by patient and procedure characteristics. We have treated 
known confounders (age group, sex, previous operation of the 
knee, diagnosis, and prosthesis brand—except when compar-
ing brands) by using adjustment in the statistical model. To 
assess possible effect modification  by time of operation, the 
analyses were also performed stratified by time periods. How-
ever, differences in survival may also be confounded by sur-
geon-related factors and by other variables not reported to the 
register. The results should therefore be interpreted with cau-
tion for brands used in a restricted number of hospitals since 
skill of the surgeons involved, follow-up routines, and revision 
threshold may have biased the results. The practice in practi-
cally all hospitals in Norway is that implant brand and use or 
non-use of patella resurfacing are decided for all patients by 
the medical director of each orthopedics department. Thus, the 
choice of brand and use of primary patella resurfacing is not 
normally linked to the surgeon or patient characteristics.
The surgeons can report several reasons for revision simul-
taneously to the NRL. This could possibly have biased some 
of our findings regarding specific reasons for revision. An 
exception is the result of pain alone as a cause of revision.
Future research
The main argument for resurfacing the patella at the primary 
TKA is to avoid anterior knee pain and the need of secondary 
patella resurfacing, at the possible cost of increasing the risk 
of serious complications related to the patellar component. A 
recent study from the AOANJRR found more revisions after 
secondary resurfacing of the patella than after primary inser-
tion of a patellar component (Clements et al. 2010). Since 
recent studies (Johnston et al. 2009, Lygre et al. 2010) have 
found no or negligible differences in pain between patients 
with a primary PR or a patella NR TKA, there should be more 
investigation of patients’ perceptions of the effect of second-
ary patella resurfacing. 
Studies of rare events such as revisions for specific reasons 
need large numbers of observations. We have studied this for 
PR and patella NR knee prostheses, and our findings need to 
be verified by other studies. Studies on differences in reasons 
for revision related to prosthesis brands are needed to improve 
the quality of TKA further. The Nordic Arthroplasty Regis-
ter Association has recently started work with establishment 
of a common Nordic database in order to pool data from the 
arthroplasty registers in Denmark, Norway, and Sweden (Rob-
ertsson et al. 2010). This could help to minimize the time nec-
essary to gather enough data for investigation of rare events. 
A recent study from the NAR has shown a higher risk of 
revision of TKAs due to infection for patients with rheumatoid 
arthritis as compared to osteoarthritis of the knee, especially 
after 5 years of follow-up (Schrama et al. 2010). More knowl-
edge of differences in risk of revision for different diagno-
ses (and for different prosthesis designs) is still needed, and 
should be focused on in future studies. 
Possible implications
Our study indicates a need to reconsider the widely accepted 
recommendation of primary resurfacing of the patella. Less 
use of a patellar component during primary TKA might be 
advisable. This will probably give advantages in terms of less 
extensive operation procedure, shorter duration of the opera-
tion (Furnes et al. 2002), better preservation of the soft tissue 
of the patella, less periprosthetic patella fractures (Chalidis et 
al. 2007), less total wear of polyethylene, less loosening of the 
tibial component, and lower cost.
Conclusion
We found a lower risk of revision of patella resurfaced TKAs 
compared to patella non resurfaced TKAs, but the difference 
was not statistically significant. There were, however, differ-
ences in reasons for revision. Resurfaced implants had sta-
tistically significantly higher risk of revision due to aseptic 
loosening of the tibial component and due to wear of a poly-
ethylene insert, but had a statistically significantly lower risk 
of revision due to pain alone. Furthermore, our results might 
also indicate that the introduction of newer implants and the 
stop in use of some older inferior designs have improved the 
survivorship of TKAs in Norway.
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